NASDAQ · CNTB
Healthcare · Biotechnology
$0.80
Down-$0.03 (-3.97%)
Updated Nov 2, 2026, 5:19 AM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CNTB
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
CNTB closed at $0.80 after 20 trading sessions, down 10.66% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $0.827 | $0.8749 | $0.78 | $0.8022 | 2.5M |
| Oct 29, 2026 | $0.8494 | $0.8541 | $0.815 | $0.8354 | 248.58K |
| Oct 28, 2026 | $0.8332 | $0.8579 | $0.8201 | $0.8453 | 359.8K |
| Oct 27, 2026 | $0.84 | $0.856 | $0.8084 | $0.8425 | 570.81K |
| Oct 26, 2026 | $0.7854 | $0.8863 | $0.75 | $0.8489 | 1.75M |
| Oct 23, 2026 | $0.76 | $0.7799 | $0.735 | $0.7665 | 344.58K |
| Oct 22, 2026 | $0.80 | $0.8195 | $0.7319 | $0.7621 | 1.07M |
| Oct 21, 2026 | $0.88 | $0.8985 | $0.787 | $0.7981 | 1.58M |
| Oct 20, 2026 | $0.8949 | $0.9198 | $0.875 | $0.8752 | 339.53K |
| Oct 19, 2026 | $0.895 | $0.9138 | $0.8641 | $0.8998 | 1.01M |
| Oct 16, 2026 | $0.89 | $0.9087 | $0.87 | $0.9063 | 575.61K |
| Oct 15, 2026 | $0.8937 | $0.9284 | $0.88 | $0.9062 | 1.52M |
| Oct 14, 2026 | $0.8936 | $0.9284 | $0.8701 | $0.909 | 1.1M |
| Oct 13, 2026 | $0.90 | $0.931 | $0.8736 | $0.9188 | 1.78M |
| Oct 12, 2026 | $0.9082 | $0.933 | $0.88 | $0.9057 | 1.62M |
| Oct 9, 2026 | $0.8745 | $0.9258 | $0.87 | $0.87 | 1.06M |
| Oct 8, 2026 | $0.93 | $0.9568 | $0.88 | $0.8807 | 1.21M |
| Oct 7, 2026 | $0.90 | $0.9689 | $0.89 | $0.9447 | 1.22M |
| Oct 6, 2026 | $0.886 | $0.98 | $0.8501 | $0.9054 | 1.84M |
| Oct 5, 2026 | $0.927 | $0.97 | $0.89 | $0.8979 | 1.43M |
The latest Smart Investors Daily articles mentioning CNTB.
Company
Market Activity
Research & News
CNTB research
Company profile and research snapshot.
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 28, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 8, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 2, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 30, 2026 | BTIG | Buy | — |
| Sep 22, 2026 | Oppenheimer | Outperform | — |
No generated briefing is available yet.
Benzinga · Oct 28, 2026
HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $7 price target.
SeekingAlpha · Oct 23, 2026
Yahoo · Oct 22, 2026
Connect Biopharma Holdings (CNTB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Yahoo · Oct 19, 2026
Connect Biopharma Holdings (CNTB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CNTB.
